Clinical Trial Update: Sitagliptin Versus Placebo in the Treatment of Non-alcoholic Fatty Liver Disease [Phase 2]

View source ↗

Summary

Phase 2 trial comparing sitagliptin to placebo in non-alcoholic fatty liver disease has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-alcoholic Fatty Liver Disease

Drugs mentioned

• Sitagliptin (sitagliptin)

Snippet

Sponsor: University of California, San Diego | Conditions: Non-alcoholic Fatty Liver Disease | Phase 2 | Status: COMPLETED | Results posted: 2016-10-20